We now have new knowledge for suggesting optimal strategies in using adjuvant for therapeutic cancer vaccines. Increasing interest is given to combinatorial approaches to augment immune T-cell responses, with the use of synergistic adjuvants. In addition, new adjuvants are being developed, such as αGalCer analogs that could be used as therapeutic agents to switch immune response towards Th1 or Th2. In view of this, we may envisage that the following years will see a considerable advance in adjuvant combination strategies or in the development of new adjuvants for therapeutic cancer vaccines. Results from some ongoing trials based on these new rationales will provide information on the clinical potential of these new strategies in the management of at least some human malignancies.
The authors are grateful to Sandrine Crabe for helpful and constructive critical comments in the preparation of the manuscript.
Financial & competing interests disclosure
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
No writing assistance was utilized in the production of this manuscript.
Expert Rev Vaccines. 2011;10(8):1207-1220. © 2011 Expert Reviews Ltd.
Cite this: Outlining Novel Cellular Adjuvant Products for Therapeutic Vaccines Against Cancer - Medscape - Aug 01, 2011.